J9349 Injection, tafasitamab-cxix, 2 mg
Billable / valid for submission HCPCS Release 2026Q3
Short description: Inj., tafasitamab-cxix
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, tafasitamab-cxix, 2 mg | yes |
Related codes in J93
- J9301 Injection, obinutuzumab, 10 mg
- J9302 Injection, ofatumumab, 10 mg
- J9303 Injection, panitumumab, 10 mg
- J9304 Injection, pemetrexed (pemfexy), 10 mg
- J9305 Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 Injection, pertuzumab, 1 mg
- J9307 Injection, pralatrexate, 1 mg
- J9308 Injection, ramucirumab, 5 mg
- J9309 Injection, polatuzumab vedotin-piiq, 1 mg
- J9311 Injection, rituximab 10 mg and hyaluronidase
- J9312 Injection, rituximab, 10 mg
- J9313 Injection, moxetumomab pasudotox-tdfk, 0.01 mg
- J9314 Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg
- J9316 Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
- J9317 Injection, sacituzumab govitecan-hziy, 2.5 mg
- J9318 Injection, romidepsin, non-lyophilized, 0.1 mg
- J9319 Injection, romidepsin, lyophilized, 0.1 mg
- J9320 Injection, streptozocin, 1 gram
- J9321 Injection, epcoritamab-bysp, 0.16 mg
- J9322 Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg